文献速递血栓与止血MDS 与骨髓增殖性肿瘤

如何治疗骨髓增殖性肿瘤患者的血栓并发症

How I approach the treatment of thrombotic complications in patients with myeloproliferative neoplasms.
PubMed 文献 · Blood · 2025-01-01

骨髓增殖性肿瘤(MPN)患者的主要并发症是动脉和静脉血栓,治疗目标是降低血栓风险。约20%的病例以血栓并发症为首发表现。本综述通过病例讨论探讨MPN患者血栓并发症的管理,包括抗血栓治疗的性质和持续时间、降细胞治疗的方法,特别关注直接口服抗凝药的应用以及MPN患者内脏静脉血栓的处理。

要点

  • 无血栓史的MPN患者,一级预防主要使用阿司匹林,高危患者加用降细胞治疗。
  • 约20%的MPN病例以血栓并发症为首发表现,需同时启动抗血栓治疗和降细胞治疗。
  • 初始静脉血栓栓塞事件后抗凝治疗的持续时间尚有讨论空间。

核心结论

  • 本综述通过病例讨论探讨MPN患者血栓并发症的管理,涉及抗血栓治疗的性质和持续时间以及降细胞治疗的方法。
  • 特别关注直接口服抗凝药的应用以及MPN患者内脏静脉血栓的处理。

研究设计与样本

  • 综述,采用基于病例的讨论形式。

主要发现

  • 动脉和静脉血栓是MPN患者最显著的并发症,主要治疗目标是降低血栓风险。
  • 无血栓史的MPN患者,一级预防主要涉及阿司匹林的使用,高危患者加用降细胞治疗。
  • 约20%的病例中,血栓并发症可揭示MPN的存在。
  • 初始静脉血栓栓塞事件后抗凝治疗的持续时间有待讨论。
  • 已知MPN诊断的患者发生血栓并发症时,需重新考虑抗血栓和血液学管理。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Arterial and venous thromboses are the most significant complications in patients with myeloproliferative neoplasms (MPNs), with the primary treatment goal being thrombotic risk reduction. In MPN with no history of thrombosis, primary prevention mainly involves the use of aspirin, and cytoreduction is added in high-risk patients. However, thrombotic complications can unveil an MPN in ∼20% of cases, necessitating the initiation of both antithrombotic therapy for the thrombosis and cytoreductive treatment for the MPN. The duration of anticoagulant therapy after an initial venous thromboembolic event is subject to discussion. Furthermore, the occurrence of a thrombotic complication in patients with a known diagnosis of MPN prompts a reconsideration of both antithrombotic and hematologic management. This review uses case-based discussions to explore the management of thrombotic complications in patients with MPN. It addresses the nature and duration of antithrombotic treatments, as well as the approach to cytoreduction. Special attention is given to the place of direct oral anticoagulants and to the management of patients with MPN with splanchnic vein thrombosis, which is disproportionately common in this group.

来源:Blood,查看原文。版权归原作者所有。

引用

  1. Guy A, Morange PE, James C, et al. How I approach the treatment of thrombotic complications in patients with myeloproliferative neoplasms. Blood. 2025. PMID: 39541574. doi:10.1182/blood.2024025627

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。